{"disease":{"id":"al-amyloidosis","name":"al amyloidosis"},"drugs":{"marketed":[{"drug_id":"daratumumab","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex","generic_name":"daratumumab","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"CD38","drug_class":"Monoclonal antibody","quality_score":10,"revenue":"11800","mechanism":"Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP."},{"drug_id":"cyclophosphamide","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"hyaluronidase","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wydase","generic_name":"HYALURONIDASE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"hyaluronic acid","drug_class":"Endoglycosidase","quality_score":10,"revenue":"900","mechanism":"Hyaluronidase increases tissue permeability by breaking down hyaluronic acid, promoting the diffusion and absorption of injected fluids."},{"drug_id":"velcade","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Velcade","company_name":"University of Arkansas","drug_phase":"marketed","molecular_target":"26S proteasome non-ATPase regulatory subunit 1, PH and SEC7 domain-containing protein 1, Cathepsin G","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bortezomib","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velcade","generic_name":"bortezomib","company_name":"Shilpa","drug_phase":"marketed","molecular_target":"26S proteasome chymotrypsin-like activity","drug_class":"Proteasome inhibitor","quality_score":76,"revenue":null,"mechanism":"Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"chembl-chembl1200796","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"darzalex","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Darzalex","company_name":"Shanghai Henlius Biotech","drug_phase":"marketed","molecular_target":"Lymphocyte differentiation antigen CD38","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cyclophosphamid","indication_name":"Systemic AL amyloidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":11,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT04937777","title":"A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":4481,"lead_sponsor_name":"European Myeloma Network B.V.","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT01164241","title":"Natural History of Severe Allergic Inflammation and Reactions","phase":"","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT06383143","title":"Promoting Diagnosis and Management of AL in Italy (ProDigALIty)","phase":"","overall_status":"RECRUITING","enrollment_count":760,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06414746","title":"Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04210791","title":"Autologous Stem Cell Transplantation for Patients With AL Amyloidosis","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Nanjing University School of Medicine","has_results":false},{"nct_id":"NCT06205953","title":"A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT03190577","title":"Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06022939","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":338,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT03984877","title":"Impact of Amyloidosis on TAVI Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Javier López Pais","has_results":false},{"nct_id":"NCT04512235","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":281,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04973137","title":"A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":208,"lead_sponsor_name":"Prothena Biosciences Ltd.","has_results":true},{"nct_id":"NCT03923920","title":"Screening for Systemic Amyloidosis Via the Ligamentum Flavum","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT06458374","title":"ATTR Cardiac Amyloidosis in a Selected Population","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Helse Møre og Romsdal HF","has_results":false},{"nct_id":"NCT05652335","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01737398","title":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02175004","title":"Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":135,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04504825","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05028374","title":"COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Barbara Ann Karmanos Cancer Institute","has_results":true},{"nct_id":"NCT07448779","title":"Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06376214","title":"Daratumumab for Patients With Light Chain Amyloidosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Nanjing University School of Medicine","has_results":false},{"nct_id":"NCT07448935","title":"One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06186167","title":"Amyloidosis Incidence in High-Risk Cardiac Device Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Midwest Heart & Vascular Specialists","has_results":false},{"nct_id":"NCT05898646","title":"Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07081646","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":91,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03154047","title":"Study in Subjects With Light Chain (AL) Amyloidosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":80,"lead_sponsor_name":"Prothena Biosciences Ltd.","has_results":true},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT06627309","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT07103863","title":"Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":49,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT06569147","title":"Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":49,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03211676","title":"Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer","phase":"NA","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT03728634","title":"Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04160351","title":"A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Selayang Hospital","has_results":false},{"nct_id":"NCT03499808","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT06192979","title":"Optimize First-line Treatment for AL Amyloidosis With t (11; 14)","phase":"NA","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Jin Lu, MD","has_results":false},{"nct_id":"NCT04131309","title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Stichting European Myeloma Network","has_results":false},{"nct_id":"NCT07335887","title":"Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":39,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03431896","title":"Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis","phase":"","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"The Cleveland Clinic","has_results":false},{"nct_id":"NCT05145816","title":"Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT06629818","title":"Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT07085559","title":"Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT07079423","title":"Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04617925","title":"A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Stichting European Myeloma Network","has_results":false},{"nct_id":"NCT02245867","title":"Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04392960","title":"Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06935162","title":"Teclistamab in Previously Treated AL Amyloidosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03236792","title":"Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}